Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.

Experimental and molecular pathology - 1 Dec 2019

Hoyt Brian S, Yan Shaofeng, Linos Konstantinos D, Momtahen Shabnam, Sriharan Aravindhan, Tran Tien-Anh N, Tsongalis Gregory J, O'Meara Rebecca R, Green Donald C, LeBlanc Robert E

Abstract excerpt

BRAF V600E is the predominant oncogenic driver of L-group histiocytoses, which includes Erdheim-Chester disease (ECD); however, limited data exist on the prevalence of this mutation in sporadic XG family lesions. This study sought to determine the incidence of BRAF V600E mutation in a clinically annotated cohort of patients with xanthogranulomas (XG) and reticulohistiocytomas (RH). A retrospective review of 58...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biomarkers, Tumor

Share to Follow-Up Studies

Share to Mutation

Share to Prognosis

Share to Young Adult

Source

Identifiers

PMID: 31639332
DOI: 10.1016/j.yexmp.2019.104320

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease.PMID 31639332Read ↗

[Clinical and pathologic characteristics of Erdheim-Chester disease].Semantic proximity Read ↗

High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses.Semantic proximity Read ↗

BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease.Semantic proximity Read ↗

Comparative Study of Clinical, Pathological, Radiological, and Genetic Features of Patients With Adult Ocular Adnexal Xanthogranulomatous Disease, Erdheim-Chester Disease, and IgG4-Related Disease of the Orbit/Ocular Adnexa.Semantic proximity Read ↗

How I diagnose Erdheim-Chester disease.Semantic proximity Read ↗

Does the BRAF(V600E) mutation herald a new treatment era for Erdheim-Chester disease? A case-based review of a rare and difficult to diagnose disorder.Semantic proximity Read ↗

Erdheim-Chester disease: a comprehensive review from the ophthalmologic perspective.Semantic proximity Read ↗

NTRK expression is common in xanthogranuloma and is associated with the solitary variantSemantic proximity Read ↗

Erdheim-Chester disease.Semantic proximity Read ↗

Evaluation of clinicopathologic characteristics and the BRAF V600E mutation in Erdheim-Chester disease among Chinese adults.Semantic proximity Read ↗

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesisSemantic proximity Read ↗

Erdheim-Chester Disease with BRAF V600E Mutation and a Concomitant Myeloid Malignancy Sharing NRAS and IDH2 Mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.